Please login to the form below

Not currently logged in
Email:
Password:

simtuzumab

This page shows the latest simtuzumab news and features for those working in and with pharma, biotech and healthcare.

Boehringer bolsters NASH pipeline with $870m Yuhan deal

Boehringer bolsters NASH pipeline with $870m Yuhan deal

Among the big players is Gilead, which recently reported two failed phase 3 trials for ASK1 inhibitor selonsertib and has previously had to abandon two other candidates (simtuzumab and Px-102).

Latest news

More from news
Approximately 1 fully matching, plus 14 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

Emotion-driven clinical trial marketing: A missed opportunity?
Whether we’re conscious of it or not, our emotions play a huge role in day-to-day decision making. Psychological scientists have long explored emotional influences on decision making. Experts like Herbert...
Virtual Hackathon on Healthcare Innovation: a Customer Story
How participants from 9 different countries in the APAC region were brought together to participate in a pharmaceutical company-wide 3-day virtual "hackathon," with spectacular results....
OPEN Health at the World Orphan Drug Conference USA
Our Director of Rare Disease, Gavin Jones looks forward to his conversation with Emily Crossle & Betsy Bogard at #WODCUSA2020 !...

Infographics